Ichihara T, Akagi M, Mori K, Ikei S, Sakamoto K, Katauchi S, Beppu T, Nokano M, Tuni K
Gan To Kagaku Ryoho. 1985 Oct;12(10):1944-5.
Transcatheter hepatic arterial embolization therapy (TAE) is an established method for the treatment of hepatocellular carcinoma (HCC). We have developed a new embolus consisting of microspheres with a mean diameter of about 200 microns which are composed of biodegradable polymolecular polylactic and the anti-cancer agent, aclarubicin -HCl, in a ratio of 12% w/w. These microspheres were applied to 28 patients with inoperable HCC using the following method microspheres containing 50 mg of aclarubicin-HCl were injected through a catheter placed in the hepatic artery or one of its branches, 2 or 3 times at intervals of 2 to 4 weeks. The effectiveness was confirmed by decreased levels of serum AFP and regression of the tumor size, and the accumulated survival rate for 6 months was 83.3%.
经导管肝动脉栓塞治疗(TAE)是一种治疗肝细胞癌(HCC)的成熟方法。我们研发了一种新的栓塞剂,它由平均直径约200微米的微球组成,这些微球由可生物降解的多分子聚乳酸和抗癌药物盐酸阿克拉霉素按12% w/w的比例构成。使用以下方法将这些微球应用于28例无法手术的HCC患者:通过置于肝动脉或其分支之一的导管,每隔2至4周注射2至3次含50毫克盐酸阿克拉霉素的微球。血清甲胎蛋白水平降低和肿瘤大小缩小证实了其有效性,6个月的累积生存率为83.3%。